An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Study Details
Study Description
Brief Summary
This is a open label clinical trial to evaluate the safety and immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., in healthy population aged 9-17 years old in comparison with aged 18-26.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 9-17y (0,6m) Subjects who aged 9-17 years old would receive 2 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) . |
Biological: 2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
Two doses administered intramuscularly at 0 and 6 month.
|
| Experimental: 9-17y (0,1,6m) Subjects who aged 9-17 years old would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) . |
Biological: 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
Three doses administered intramuscularly at 0, 1 and 6 month.
|
| Experimental: 18-26y (0,1,6m) Subjects who aged 18-26 years old would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) . |
Biological: 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
Three doses administered intramuscularly at 0, 1 and 6 month.
|
Outcome Measures
Primary Outcome Measures
- Immunogenicity1: Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific antibody levels at Months 7 in the population aged 9-26 years old receiving 3 doses of the nanovalent vaccine [7 months after the first dose]
To determine whether the immune responses (antibodies to HPV-6, 11, 16, 18, 31, 33, 45, 52, and 58) at month 7 (one month after the final dose) in the population aged 9-17 years receiving 3 doses of the nanovalent vaccine are noninferior to those in women aged 18-26 years receiving 3 doses of vaccine.
Secondary Outcome Measures
- Immunogenicity2: Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific antibody levels at Months 7 in the population aged 9-17 years old receiving 2 doses of the nanovalent vaccine [7 months after the first dose]
To determine whether the immune responses (antibodies to HPV-6, 11, 16, 18, 31, 33, 45, 52, and 58) at month 7 (one month after the final dose) in the population aged 9-17 years receiving 2 doses of the nanovalent vaccine are noninferior to those in women aged 18-26 years receiving 3 doses of vaccine.
- Safety1: Local and systematic adverse events/reactions occurred within 7 days after each vaccination. [During the 7-day period following each vaccination]
Local and systematic adverse events/reactions occurred within 7 days after each vaccination.
- Safety2: Adverse events/reactions occurred within 30 days after each vaccination. [Within 30 days (Day 0-30) after any vaccination]
Adverse events/reactions occurred within 30 days after each vaccination.
- Safety3: Severe adverse events occurred throughout the study. [Up to 8 month]
Severe adverse events occurred throughout the study. To evaluate number of SAEs between the different arms.
- Safety4: Pregnancy and pregnancy outcome. [Up to 8 month]
Pregnancy and pregnancy outcome. To evaluate number of births and terminations between the different arms.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject is female between and including 9-26 years of age, or male between and including 9-17 years of age at the first vaccination;
-
Subject (and their legal guardian) is able to understand and comply with the requirements of the protocol(e.g. biological specimen collection, completion of the diary cards, return for follow-up visits), and written informed consent must be obtained from the subject prior to enrollment;
-
Adolescent female subject who agrees to practice effective contraception within 8 months after the first vaccination or has undergone tubal ligation,subtotal hysterectomy for benign lesion, ovarian benign tumor resection;
-
No previous history of sexually transmitted diseases (including syphilis, gonorrhea, chancroid, venereal lymphogranuloma, groin granuloma, etc.);
-
Male, or female without previous history of abnormal cervical screening results or cervical intraepithelial neoplasia (CIN);
Exclusion Criteria:
-
Axillary temperature > 37.2℃;
-
Adolescent female subject who has a positive urine pregnancy test, or is pregnant or breastfeeding;
-
Subject has used of any investigational or non-registered product (drug or vaccine) within 30 days preceding the first dose of study vaccine or plans to use during the study period , or has participated in another clinical research in the past two years, or plans to participate in another research during the study period;
-
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs or systemic corticosteroids (Except intranasal steroid, the use of low dose topical, ophthalmic and inhaled steroid preparations will be permitted.) within 6 months prior to vaccination.
-
Administration of immunoglobulin and/or blood products within 3 months prior to vaccination or planned to use them within 7 months after the first dose.
-
Administration of inactivated vaccine within 14 days prior to vaccination or live vaccine within 21 days;
-
Fever (Axillary temperature ≥38.0℃) 3 days prior to vaccination or system administration of antibiotics or antiviral agents within 5 days, or medicines containing antipyretic ingredients within 24 hours prior to vaccination;
-
Subject has received other HPV vaccines or participated in clinical research related to HPV or cervical cancer previously;
-
Subject has severe immunodeficiency disease, severe primary disease of important viscera, cancer and autoimmune disease (including systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy due to any condition, and other immunological diseases that investigators believe may influence the immune response).
-
History of severe allergy (e.g., anaphylaxis, generalized urticaria, dyspnea, angioedema, and other significant reaction) to any previous vaccination, or be allergic to any of the components of the study vaccines.
-
Asthma, which has been unstable for the past two years and requires emergency treatment, hospitalization, oral or intravenous corticosteroids;
-
Subject has serious medical disorders;
-
Self-report (subject and their legal guardian) coagulation disorders or abnormal coagulation function;
-
Epilepsy, excluding febrile epilepsy under 2 years of age, alcoholic epilepsy 3 years prior to abstinence or simple epilepsy that does not require treatment in the past 3 years;
-
Medical, psychological, social conditions, occupation or other factors, which considered by the investigator that may influence the conduct of the clinical study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sichuan Provincial Centre for Disease Control and Prevention | Chengdu | Sichuan | China | 610041 |
Sponsors and Collaborators
- Xiamen University
- Xiamen Innovax Biotech Co., Ltd
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Investigators
- Study Chair: Jun Zhang, master, Xiamen University
- Principal Investigator: Xue-cheng Liu, master, Sichuan Provincial Centre for Disease Control and Prevention
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HPV-PRO-012